Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Will amalgamation be a catalyst?

<< Previous

Bullboard Posts

Next >>

Comment by 3burtcon May 02, 2021 9:38am

308 Views

Post# 33110287

RE:RE:RE:Will amalgamation be a catalyst?

One other thing. Dan mentioned in B & B video that the shares that were privately purchased in early March are part of the Amalgamation. IF negotiations were still going on between Antibe & AH, those shares would not have been distributed suggesting negotiations between Antibe & AH are complete.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"